Chemizon Announces Further Expansion of Its Collaboration with Takeda

LONGMONT, Colo.--(BUSINESS WIRE)--Chemizon, a division of OptoMagic Co. Ltd. (KOSDAQ: 010170), announced today that Takeda Pharmaceutical Company Limited will continue, and further expand its current research collaboration that utilizes Chemizon’s Discovery Platform. The expansion will be effective beginning the 1^st of August, 2009.

“We are pleased that Takeda Pharmaceuticals, one of Chemizon’s earliest collaborators, has chosen to further extend and expand their collaboration with us,” said Dr. Tony Piscopio, Chairman and CEO of Optomagic. “This third expansion of the Chemizon-Takeda research partnership is a credit to our scientific team, and validates our efforts in achieving the strategic objectives that were laid out by Takeda. We look forward to a long and mutually beneficial relationship.”

About Chemizon

Chemizon is a collaborative drug discovery services organization with operations in South Korea, China and the United States. Our goal is to become the ‘partner of choice’ for Pharmaceutical and Biotech companies around the globe, that seek to cost-effectively enhance their internal pipelines. Our experienced, repatriated management team and skilled scientists leverage a fully integrated platform that includes medicinal chemistry, computational chemistry/structural biology, discovery biology, ADME/DMPK and pharmacology, to help our partners discover novel small molecules in the disease areas of oncology, metabolic disorders and CNS. For more information on Chemizon, please visit our web site at www.chemizon.com.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com.

Forward-looking statements

This press release may contain certain "forward-looking statements" regarding the agreement between Chemizon and Takeda Pharmaceutical Company Limited. These statements are based on Chemizon’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, collaboration potential or financial performance. None of the forward-looking statements are guaranteed, and actual results may differ materially from those projected. Chemizon may choose to update this notice in the future, based on new information, future events, or otherwise, but undertakes no obligation to do so. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Chemizon’s business, including, but not limited to, the health of the global life sciences industry, the growth of the outsourcing business model and the ability of Chemizon to derive value from successful collaborations.

Chemizon
Ramesh Subramanian, 856-637-2232
VP, Business Development
sramesh@chemizon.com